Aurobindo Pharma Share Price
(AUROPHARMA)
Check the latest share price of Aurobindo Pharma, details on performance, fundamentals, analyst ratings, peer comparison, financials, company news, analysis, and shareholding pattern for informed investing decisions.
as on 04:01PM, 02 May 2025
NSE
Aurobindo Pharma Performance
Get real-time share price information, day’s high and low, historical returns and market stats.
Day's Low
Day's High
₹1,204.5Day's Price Range₹1,248.552 Week's Low
52 Week's High
₹1,01052-Week Price Range₹1,592
| Returns % | |
| 1 Month Return | + 3.02 % |
| 3 Month Return | + 7.69 % |
| 1 Year Return | + 5.23 % |
| Market Stats | |
| Previous Close | ₹1,229.10 |
| Open | ₹1,234.00 |
| Volume | 6.31L |
| Upper Circuit | ₹1,352.00 |
| Lower Circuit | ₹1,106.20 |
| Market Cap | ₹71,009.90Cr |
Aurobindo Pharma Fundamentals & Key Indicators
Check the fundamental ratios and key indicators of the company like P/E, P/B, PEG, Dividend yield etc.
Market Cap
₹71,009.90 Cr
Return on Equity (ROE)
10.35
PE Ratio (TTM)
20.28
Return on capital employed (ROCE)
11.74
Beta (LTM)
0.82
P/B Ratio
3.24
Dividend Yield
0.41
PEG Ratio
1.62
EPS (TTM)
54.09
Sector
Pharmaceuticals
Technical Analysis
Bullish
View Technical Analysis
How to invest in Aurobindo Pharma
Investing in Aurobindo Pharma is simple. You can open a free INDstocks investment account on the INDmoney App. Search for Aurobindo Pharma or AUROPHARMA on the app to check live prices of the stock and click on Buy or SIP. You can invest by selecting the number of shares or set up a fixed SIP to invest every month or week.
For example: You can buy 10 shares of Aurobindo Pharma or start an SIP based on the market price on each investment date.
You can easily transfer money to your stock account via the INDmoney app and start investing in stocks like Aurobindo Pharma with just a few clicks!
Aurobindo Pharma Valuation
Track how the P/E of Aurobindo Pharma has moved over time to understand valuation trends.
Aurobindo Pharma in the last 5 years
Lowest (6.73x)
March 23, 2020
Today (20.28x)
May 2, 2025
Industry (54.34x)
May 2, 2025
Highest (27.59x)
December 21, 2023
Today’s Price to Earnings Ratio: 20.28x
Analysts Recommendation on Aurobindo Pharma
Get updated buy, sell, and hold recommendations by analysts on Aurobindo Pharma.
based on 28 analysts
78.57%
Buy
7.14%
Hold
14.29%
Sell
78.57% of analysts recommend a 'BUY' rating for Aurobindo Pharma. Average target price of ₹1470.82
Source: S&P Global Market Intelligence
Analysts Forecast on Aurobindo Pharma
Get share price movements and forecasts by analysts on Aurobindo Pharma.
Aurobindo Pharma price forecast by 28 analysts
Upside of21.36%
High
₹1930
Target
₹1470.82
Low
₹1140
Aurobindo Pharma target price ₹1470.82, a slight upside of 21.36% compared to current price of ₹1211.9. According to 28 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Aurobindo Pharma revenue growth forecast
Expected growth rate Q1, FY2027:28.08%
Forecast
Actual
Including amortisation and stock based compensations
Aurobindo Pharma EPS growth forecast
EPS estimate Q1, FY2027:50.78%
Forecast
Actual
Source: S&P Global Market Intelligence
Aurobindo Pharma Financials
Get the annual and quarterly financial summary of Aurobindo Pharma, including revenue, profit, loss and more.
Aurobindo Pharma Index Inclusions
Aurobindo Pharma Earnings and Dividends
View detailed summary of the earnings and dividend history of Aurobindo Pharma.
Aurobindo Pharma Ltd Earnings Results
Aurobindo Pharma Ltd’s net profit fell -9.66% since last year same period to ₹845.81Cr in the Q3 2024-2025. On a quarterly growth basis, Aurobindo Pharma Ltd has generated 3.48% jump in its net profits since last 3-months.
Read More about Earnings ResultsAurobindo Pharma Ltd Dividends February,2024
In the quarter ending December 2023, Aurobindo Pharma Ltd has declared dividend of ₹1.50 - translating a dividend yield of 0.37%.
Read More about Dividends
Aurobindo Pharma Shareholding Pattern
View the shareholding pattern breakup of promoters, FIIs, DIIs, and retail investors in Aurobindo Pharma.
| Investors | Holdings % | Quarterly Trend | 3M change |
|---|---|---|---|
| Promoter Holdings | 51.82% | 0.00 | |
| Foreign Institutions | 15.33% | 0.00 | |
| Mutual Funds | 18.21% | 0.00 | |
| Retail Investors | 6.61% | 0.00 | |
| Others | 8.03% | 0.00 |
Aurobindo Pharma vs Peers
Compare market cap, revenue, PE, and other key metrics of Aurobindo Pharma with its industry peers.
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
|---|---|---|---|---|---|---|
| BUY | ₹71,009.90 Cr | 17.1% | 0.56 | ₹3,168 Cr | ₹29,001 Cr | |
| BUY | ₹13,704.00 Cr | -5.22% | 0.52 | ₹413 Cr | ₹2,013 Cr | |
| HOLD | ₹89,112.08 Cr | 33.64% | 0.64 | ₹3,854 Cr | ₹19,547 Cr | |
| BUY | ₹65,290.63 Cr | 13.77% | 0.53 | NA | NA | |
| BUY | ₹48,328.15 Cr | 18.54% | 0.56 | ₹589 Cr | ₹3,453 Cr |
Aurobindo Pharma News & Key Events
Latest news and events at one place to help you take investing decisions in Aurobindo Pharma.
Fire Incident Halts Aurobindo Pharma Operations Temporarily - 28 Apr, 2025
Aurobindo Pharma reported a fire at its Kakinada facility, leading to a 20-25 day pause in operations. Fortunately, there were no injuries, and the core infrastructure remains intact. The facility is fully insured, and the company is committed to resuming operations promptly.Aurobindo Pharma's Biosimilar Dazublys Gains EMA Approval - 26 Apr, 2025
Aurobindo Pharma's subsidiary, CuraTeQ Biologics, received a positive opinion from the EMA for Dazublys, a trastuzumab biosimilar, enhancing treatment options for HER2-positive breast cancer.Aurobindo Pharma Secures USFDA Approval for Dasatinib - 23 Apr, 2025
Aurobindo Pharma's subsidiary, Eugia Pharma, received USFDA approval for Dasatinib Tablets, a leukemia treatment, expected to launch in FY26, targeting a $1.8 billion market.Aurobindo Pharma Stock Shows Strong Momentum - 22 Apr, 2025
Aurobindo Pharma's stock has risen over 14% from a recent low of ₹1,050, currently trading at ₹1,200. It remains above its 100-DMA for two consecutive sessions, supported by positive momentum indicators.Aurobindo Pharma Gains USFDA Approval for Rivaroxaban - 12 Apr, 2025
Aurobindo Pharma has received USFDA approval for Rivaroxaban Tablets USP, 2.5 mg, with a market potential of $447 million. Tentative approvals for higher strengths could lead to a total market size of $8.5 billion, enhancing Aurobindo's position in the US market.Aurobindo Pharma Faces FDA Scrutiny Amid Trial Success - 11 Apr, 2025
Aurobindo Pharma shares surged 5% following positive Phase 1 trial results for BP16, while the company also faced FDA scrutiny at its North Carolina plant, receiving a Form 483 with 11 observations. The company is committed to addressing these observations without expecting material impact on operations.Aurobindo Pharma Completes Phase 1 Trials for BP16 - 10 Apr, 2025
Aurobindo Pharma's subsidiary, CuraTeQ Biologics, successfully completed Phase 1 trials for BP16, a new bone treatment. However, the stock has declined 9% weekly and 22-23% year-to-date.Aurobindo Pharma Faces Tariff Threats Amid Drug Success - 09 Apr, 2025
On April 9, Aurobindo Pharma faced a stock decline due to Trump's tariff threats while also reporting successful Phase 1 trial results for osteoporosis drug BP16.Aurobindo Pharma Gains EU Approval Amid Profit Decline - 07 Apr, 2025
Aurobindo Pharma's subsidiary, CuraTeQ Biologics, received EU approval for Dyrupeg, a biosimilar. However, the company reported a 10.04% decline in Q3 FY25 net profit.Aurobindo Pharma Secures EU Approval for Dyrupeg - 05 Apr, 2025
Aurobindo Pharma's subsidiary, CuraTeQ Biologics, received EU marketing authorization for Dyrupeg™, a pegylated filgrastim biosimilar. This approval enhances Aurobindo's biosimilar portfolio in Europe, providing a cost-effective treatment option for patients with low white blood cell counts.Aurobindo Pharma Shares Plummet Amid Tariff Concerns - 04 Apr, 2025
On April 4, 2025, Aurobindo Pharma's shares dropped significantly, falling up to 10% due to U.S. President Trump's remarks about impending tariffs on pharmaceutical imports.Aurobindo Pharma Shares Surge After Tariff Exemption - 03 Apr, 2025
Aurobindo Pharma's stock jumped 7.36% on April 3, 2025, following the U.S. administration's exemption of pharmaceuticals from reciprocal tariffs, benefiting the company's significant U.S. revenue exposure.Aurobindo Pharma Faces Potential Tariff Challenges - 02 Apr, 2025
Aurobindo Pharma may experience margin pressure due to potential tariffs of up to 35% on exports, affecting its substantial revenue from the US market.
Insights on Aurobindo Pharma Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTPrice Rise
In the last 3 months, AUROPHARMA stock has moved up by 7.7%
- POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 10 quarters, 5.79K Cr → 8.13K Cr (in ₹), with an average increase of 3.7% per quarter
- POSITIVE IMPACT
Profit Spike
Netprofit is up for the last 2 quarters, 817.38 Cr → 845.81 Cr (in ₹), with an average increase of 3.4% per quarter
- POSITIVE IMPACT
MF Holding Up
Mutual Funds have increased holdings from 17.81% to 18.21% in Mar 2025 quarter
NO EFFECTPromoter Holding Unchanged
Promoters holdings remained unchanged at 51.82% of holdings in Mar 2025 quarter
- NO EFFECT
Against Peers
In the last 1 year, Divis Laboratories Ltd has given 54.5% return, outperforming this stock by 49.3%
- NO EFFECT
Against Peers
In the last 3 years, Torrent Pharmaceuticals Ltd has given 141.8% return, outperforming this stock by 47.8%
NEGATIVE IMPACTFII Holding Down
Foreign Institutions have decreased holdings from 16.29% to 15.33% in Mar 2025 quarter
- NEGATIVE IMPACT
Retail Holding Down
Retail Investor have decreased holdings from 6.69% to 6.61% in Mar 2025 quarter
About Aurobindo Pharma
The company is well known for its top products such as antibiotics, anti-malarials, cardiovascular, and anti-diabetic drugs. Its popular brands include Aurolife, Aurocare, Aurochem, and Aurovit. Aurobindo Pharma is one of the largest manufacturers of generic drugs in India, with a presence in over 150 countries worldwide.
Revenue: ₹7,893.15Cr as on December 2024 (Q4 24)
Net Profit: ₹845.57Cr as on December 2024 (Q4 24)
Listing date: 19 Oct, 1995
Chairperson Name: K Ragunathan
| Organisation | Aurobindo Pharma Ltd |
| Headquarters | Hyderabad |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
Indian Mutual Funds that own Aurobindo Pharma
Check out the Mutual Funds with significant holdings in Aurobindo Pharma.
FAQs
What is Aurobindo Pharma Ltd price today?
Aurobindo Pharma Ltd share price today stands at ₹1211.9, Open: ₹1234, Previous Close: ₹1229.1, High: ₹1248.5, Low: ₹1204.5, 52 Week High: ₹1592, 52 Week Low: ₹1010.
How to Buy Aurobindo Pharma Ltd Share in India?
- Get a PAN card
- Open a Demat account
- Open a Trading account
- Link your Demat account to your Trading account
- Fund your Trading account
- Place an order to buy Aurobindo Pharma Ltd shares
What are today's traded volumes of Aurobindo Pharma Ltd?
Today's traded volume of Aurobindo Pharma Ltd(AUROPHARMA) is 6.31L.
What is today's market capitalisation of Aurobindo Pharma Ltd?
Today's market capitalisation of Aurobindo Pharma Ltd(AUROPHARMA) is ₹71,009.90 Cr.
What is the 52 Week High and Low Range of Aurobindo Pharma Ltd?
How much percentage Aurobindo Pharma Ltd is down from its 52 Week High?
Aurobindo Pharma Ltd (AUROPHARMA) share price is ₹1211.9. It is down -23.88% from its 52 Week High price of ₹1592
How much percentage Aurobindo Pharma Ltd is up from its 52 Week low?
Aurobindo Pharma Ltd (AUROPHARMA) share price is ₹1211.9. It is up 19.99% from its 52 Week Low price of ₹1010